Hidradenitis suppurativa: Current and emerging treatments.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31604100.
- Also identified by DOI 10.1016/j.jaad.2019.08.089.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The treatment of hidradenitis suppurativa (HS) has remained challenging because of the many knowledge gaps regarding etiology. However, recent studies into the pathogenesis of HS have enabled the investigation of newer therapies. The second article in this continuing medical education series reviews the evidence for established therapies for HS, including anti-inflammatories, antibiotics, and surgery. New and emerging therapies that specifically target cytokines involved in HS pathogenesis will be covered. The potential therapeutic roles of anticytokine therapies, including both the expanded application of existing molecules as well as the specific development of novel therapies for HS are discussed. With increased attention on HS and with numerous clinical trials currently underway, we hope that the variety of treatment options for HS will be expanded.
Medical subject headings
- Adalimumab
- Anti-Bacterial Agents
- Anti-Inflammatory Agents
- Hidradenitis Suppurativa
- Laser Therapy
- Quality of Life